Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
151
resultados
Última actualización
03/05/2025 [06:59:00]
Resultados 25 a 50 de 151
Resumen de: US2025127431A1
The invention provides a non-invasive blood glucose monitoring device with a wearing fit detection function, comprising a substrate, a blood glucose monitoring module, an optical feedback sensing module and at least one light-blocking wall. The substrate defines a first setting area for disposing the blood glucose monitoring module and a second setting area for disposing the optical feedback sensing module. The second setting area is between an edge of the substrate and the first setting area. The optical feedback sensing module includes at least one light-emitting element and at least one light-receiving element. Each light-emitting element emits a light signal corresponding to at least one specific wavelength, and each light-receiving element receives the light signal corresponding to the at least one specific wavelength, after being reflected, as a basis for determining the wearing fit. The at least one light-blocking wall is located between the first setting area and the second setting area.
Resumen de: US2025127436A1
The present disclosure relates to a continuous glucose monitoring device, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work for a user in attaching the body attachment unit to a body and allowing attachment of the body attachment unit to the body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter and allowing easier maintenance. In addition, the continuous glucose monitoring device is activated by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and the continuous glucose monitoring device can be activated in a stabilized state, and thereby can monitor blood glucose more accurately.
Resumen de: US2025127432A1
A glucose monitoring system comprising: a glucose sensor configured to output a glucose sensor output signal indicative of an estimate of a glucose level of a user of the glucose monitoring system; a movement sensor configured to output a movement sensor output signal indicative of detected movement of the user; and a controller configured to generate an estimate of a current glucose level of the user based on the glucose sensor output signal and the movement sensor output signal.
Resumen de: US2025127435A1
A blood glucose sensing system includes a plurality of physiological sensors. The system can estimate blood glucose based on discrete invasive blood glucose estimates from a blood sample, discrete noninvasive blood glucose estimates derived from optical sensors, and continuously-calculated blood glucose estimates derived from a nonlinear state-space model of glucose and insulin reactions within a human body. The state-space model has user-entered values corresponding to their insulin and meal intake. The user's blood glucose is estimated from a combination of the discrete invasive blood glucose estimates, the discrete noninvasive blood glucose estimates and the continuously-calculated blood glucose estimate.
Resumen de: US2025127439A1
A biometric wearable device (e.g. finger ring or smart watch) has optical sensors to measure body oxygenation level, hydration level, glucose level, heart rate, heart rate variability, and/or blood pressure. Light from light emitters is transmitted through body tissue and changes in the light are analyzed. The angles and/or vectors along which the light is transmitted through body tissue can be automatically changed by the device in order to scan different tissue regions and/or different tissue depths.
Resumen de: US2025127434A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device.
Resumen de: US2025127861A1
Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic/pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.
Resumen de: US2025132007A1
A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.
Resumen de: US2025132008A1
Systems and methods for processing sensor data are provided. In some embodiments, systems and methods are provided for calibration of a continuous analyte sensor. In some embodiments, systems and methods are provided for classification of a level of noise on a sensor signal. In some embodiments, systems and methods are provided for determining a rate of change for analyte concentration based on a continuous sensor signal. In some embodiments, systems and methods for alerting or alarming a patient based on prediction of glucose concentration are provided.
Resumen de: US2025127993A1
Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.
Resumen de: EP4542574A2
Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are disclosed. In an embodiment, a method for transmitting data between a first communication device associated with an analyte sensor and a second communication device configured to provide user access to sensor-related information comprises: activating a transceiver of a first communication device associated with an analyte sensor at a first time; and establishing a two-way communication channel with the second communication device; wherein the activating comprises waking the transceiver from a low power sleep mode using a forced wakeup from the second communication device.
Resumen de: EP4541265A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; and a storage unit that stores the blood glucose measurement data, wherein the control unit stores the preset first verification data in the storage unit, and stores the blood glucose measurement data in the storage unit continuously to the first verification data.
Resumen de: EP4542560A1
Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.
Resumen de: EP4541266A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device, wherein the control unit determines the validity of the blood glucose measurement data stored in the plurality of storage areas, and controls the communication unit to transmit the blood glucose measurement data stored in at least one of the plurality of storage areas to the external device, based on a result of the determination.
Resumen de: EP4541390A2
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal dosing of GLP-1 or co-formulation of GLP-1 and insulin. The size and frequency of the basal doses may be controlled by a medication delivery algorithm resident on the wearable drug delivery device based on a basal dosing history and readings from a continuous glucose monitor monitoring the glucose levels of the wearer of the device.
Resumen de: EP4541276A1
The invention provides a non-invasive blood glucose monitoring device with a wearing fit detection function, comprising a substrate, a blood glucose monitoring module, an optical feedback sensing module and at least one light-blocking wall. The substrate defines a first setting area for disposing the blood glucose monitoring module and a second setting area for disposing the optical feedback sensing module. The second setting area is between an edge of the substrate and the first setting area. The optical feedback sensing module includes at least one light-emitting element and at least one light-receiving element. Each light-emitting element emits a light signal corresponding to at least one specific wavelength, and each light-receiving element receives the light signal corresponding to the at least one specific wavelength, after being reflected, as a basis for determining the wearing fit. The at least one light-blocking wall is located between the first setting area and the second setting area.
Resumen de: US2025120619A1
Disclosed herein are system, method, and computer program product embodiments for interconnecting a prediction visualization with user medical data for analyzing the impact of personal choices on future glucose levels. The prediction visualization is configured to generate predictions of glycemic impact based one or more inputs including choices involving diet and exercise and user medical data, such as the user's historical and current glucose levels. The prediction visualization is configured to be adjustable based on user input and the visualization is configured to dynamically update based on user input. The disclosed interface allows the user to adjust the sequencing of these decisions and portion sizes of meal choices and immediately generate new visualizations representing the impact on predicted future glucose levels.
Resumen de: US2025120616A1
Embodiments relate to a non-enzymatic glucose sensor. The non-enzymatic glucose sensor comprises one or more electrodes, a microfluidic channel, and at least one inlet, wherein the at least one inlet is configured to deliver a fluid to a microfluidic channel and wherein the microfluidic channel is configured to transport the fluid to the one or more electrodes. At least one of the one or more electrodes is a laser-induced graphene electrode, wherein the laser-induced graphene electrode comprises one or more uniform coatings of metal.
Resumen de: US2025121213A1
A dialysis-ultrasound system is described that includes an ultrasound therapy device integrated with a catheter to incorporate ultrasound therapy into a dialysis system. The ultrasound device may be or may include a high-intensity focused ultrasound (HIFU) device or peripheral focused ultrasound stimulation (pFUS) device. The ultrasound therapy may target the liver, for example, to treat diabetes. In one example, a system includes a catheter configured to be arranged within the peritoneal cavity of a patient for peritoneal dialysis (PD), and an ultrasound device configured to emit ultrasound waves. The ultrasound device is integrated with the catheter and is arranged on the catheter to be implanted within the peritoneal cavity of the patient to provide ultrasound therapy to a target region of the patient. Other embodiments are described.
Resumen de: US2025121133A1
Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.
Resumen de: US2025125031A1
A device may receive, from a plurality of sensors, sensor data relating to a user. The device may include a plurality of types of sensors including a spectrometer and one or more of an accelerometer, a heart rate sensor, a blood pressure sensor, a blood sugar sensor, a perspiration sensor, a skin conductivity sensor, or an imaging sensor. The device may process the sensor data, from the plurality of types of sensors, relating to the user to determine a health condition of the user. The device may provide, via a user interface, information identifying the health condition of the user based on processing the sensor data, from the plurality of types of sensors, relating to the user.
Resumen de: AU2023379646A1
Systems, devices and methods are provided for titration of a medication dose for a patient or user. The titration may be based on determining a hypoglycemic risk of a user for a plurality of time-of-day periods. The determination of the hypoglycemic risk may be accomplished by known methods, including the glucose pattern analysis, glucose dysregulation analysis, low alarm frequency analysis, and combinations thereof. The system may then select a recommended action based on the analyte pattern type. The system may then store an indicator of the recommended action in a computer memory for output. The system may then output the recommended action. The recommended action may be outputted to the user, an HCP, or a caregiver. The recommended action may also vary depending on who is receiving the recommended action.
Resumen de: US2025120618A1
A non-invasive blood glucose monitoring module with high optical transmittance includes a substrate, a first detecting unit and a second detecting unit. The first detecting unit includes a first light source set, a first photosensitive element and first blocking wall structures. The first photosensitive element receives light, with a first wavelength, emitted from the first light source set. The first blocking wall structures are located between the two first light-emitting elements and between the first light source set and the first photosensitive element. The second detecting unit includes a second light source set, a second photosensitive element and second blocking wall structures. The second photosensitive element receives light, with a second wavelength, emitted from the second light source set. The second blocking wall structures are located between the two second light-emitting elements and between the second light source set and the second photosensitive element.
Resumen de: WO2025076843A1
An insulin needle tip protection mechanism and an insulin injection device. According to the insulin needle tip protection mechanism, by means of the cooperation of a U-shaped reciprocating groove (3) and an elastic wall (6), a needle tip can be automatically retracted after injection, and cannot be pushed out again, so that the purpose of needle tip protection is achieved, and secondary use can also be avoided.
Nº publicación: AU2025202313A1 17/04/2025
Solicitante:
INSULET CORP
Insulet Corporation
Resumen de: AU2025202313A1
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
BOPI
Sede Electrónica
